Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers.

Rayan DakroubSolène HuardYara Hajj-YounesSamyuktha SureshBassam BadranHussein Fayyad-KazanThierry Dubois

Published in: Breast cancer (Dove Medical Press) (2023)

Altogether, our data highlight the therapeutic potential of targeting PRMT5 using combinatorial strategies for the treatment of subsets of TNBC patients.

Keyphrases

end stage renal disease
small cell lung cancer
newly diagnosed
chronic kidney disease
cancer therapy
electronic health record
epidermal growth factor receptor
tyrosine kinase
machine learning
peripheral blood
drug delivery
patient reported outcomes
replacement therapy
artificial intelligence